This unique three-part philosophy guides how we achieve our mission and vision, as well as how we approach our work with others. We do our best work with people who share this philosophy, or at least appreciate the merits of it.
Involve Multiple Stakeholders
The problem with this lopsided influence is that the insight, and subsequently the support, of other stakeholders is critical to clinical trial success. Without patients, for instance, there can be no clinical trial. And given the patient recruitment bottleneck, sponsors cannot afford to be dismissive of their needs.
To be viable, future solutions must involve multiple stakeholders, with particular attention to patients.
Be Patient-Centric By Design
The term “patient-centric” gets thrown around a lot these days. But for us, patient-centricity is much more than a buzzword. Rebar Interactive was founded upon the very idea of it.
Here’s what patient-centric means to us:
Meet Patients Where They Are
The conventional clinical trial model requires patients to conform their lives to the clinical trial. Clinical trials should instead conform to patient lives.
Help Patients Feel Connected
The conventional clinical trial model has not accounted for the innate human desire to feel connected. Clinical trials should instead help patients to connect with patients, clinical researchers, and clinical research.
Relentlessly Create Value for Patients
The conventional clinical trial model has focused primarily on creating value for the sponsor. Clinical trials should instead focus on creating value for the patient.
Incorporate Emerging Technology
For example, cloud platforms provide new ability to involve multiple stakeholders and facilitate collaboration in an efficient and scalable manner. And mobile technology presents a new opportunity to meet patients where they are, while social media can help patients to feel connected.
It’s important to emphasize that we believe technology to be the key means to improve the clinical trial model but not an end itself. Technology that is not patient-centric by design, for example, will be of limited value in advancing clinical trials.
